|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400088711 |
|
最近更新日期: Date of Last Refreshed on: |
2024-08-26 09:40:27 |
|
注册时间: Date of Registration: |
2024-08-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
益生菌含片(食品)对健康人口腔菌群的影响研究 |
|
Public title: |
Effect of probiotic lozenges (food) on oral flora of healthy people |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
益生菌含片(食品)对健康人口腔菌群的影响研究 |
|
Scientific title: |
Effect of probiotic lozenges (food) on oral flora of healthy people |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李铮 |
研究负责人: |
王月红 |
|
Applicant: |
Li Zheng |
Study leader: |
Wang Yuehong |
|
申请注册联系人电话: Applicant telephone: |
+86 157 1662 6498 |
研究负责人电话:
Study leader's |
+86 186 2753 3303 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1694914293@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
wangyuehong1999@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
长沙市开福区湘雅路72号 |
研究负责人通讯地址: |
长沙市开福区湘雅路72号 |
|
Applicant address: |
No.72 Xiangya Road, Kaifu District, Changsha City |
Study leader's address: |
No.72 Xiangya Road, Kaifu District, Changsha City |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
湖南中南大学湘雅口腔医学院(湘雅口腔医院) |
||
|
Applicant's institution: |
Xiangya School of Stomatology, Central South University, Hunan |
||
|
研究负责人所在单位: |
湖南中南大学湘雅口腔医学院(湘雅口腔医院) |
||
|
Affiliation of the Leader: |
Xiangya School of Stomatology, Central South University, Hunan |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
20240038 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
湖南中南大学湘雅口腔医院伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Review Committee, Xiangya Stomatological Hospital, Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-07 00:00:00 | ||
|
伦理委员会联系人: |
何宇清 |
||
|
Contact Name of the ethic committee: |
He Yuqing |
||
|
伦理委员会联系地址: |
长沙市开福区湘雅路72号 |
||
|
Contact Address of the ethic committee: |
No.72 Xiangya Road, Kaifu District, Changsha City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 151 1617 7313 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
xykqyxy_kyb@163.com |
|
研究实施负责(组长)单位: |
湖南中南大学湘雅口腔医学院(湘雅口腔医院) |
||||||||||||||||||||||
|
Primary sponsor: |
Xiangya School of Stomatology, Central South University, Hunan |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
长沙市开福区湘雅路72号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.72 Xiangya Road, Kaifu District, Changsha City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
江苏佰奥达生物科技有限公司、湖南自贸试验区环球细胞库有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Jiangsu Baiaoda Biotechnology Co., LTD., Hunan Free Trade Zone Global Cell Bank Co., LTD |
||||||||||||||||||||||
|
研究疾病: |
龋病 |
||||||||||||||||||||||
|
Target disease: |
dental caries |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
评估乳杆菌口含片(食品)的使用对健康人群口腔内变异链球菌数量的影响,以及停用后益生菌在口腔内的持久性。 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effects of Lactobacillus oral lozenges (live and inactivated) on the number of streptococcus mutans in the mouth of healthy people and the persistence of probiotics in the mouth after discontinuation. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
本研究采用的植物乳杆菌口含片(食品)已获得无锡市市场监督管理局下发的食品生产许可证和国家市场监督管理总局批准上市。 生产批文:食品生产许可证号SC10632028102635。 厂家:江苏佰奥达生物科技有限公司—江苏新申奥生物科技有限公司—江阴分公司。 产品文号:益生菌含片,适用压片糖果SB/T10347及食品用菌种制剂QB/T4574、Q/XSAJY0001S、Q/XSASW0015S |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
The Lactobacillus plantarum oral lozenges (food) used in this study have obtained the food production license issued by Wuxi Market Supervision Administration and the approval of the State Administration of Market Supervision and Administration. Production approval: Food production license No. SC10632028102635. Manufacturer: Jiangsu Baiaoda Biotechnology Co., Ltd.-Jiangsu Xinshenao Biotechnology Co., Ltd.-Jiangyin Branch. Product code: Probiotic lozenges, suitable for tablet candy SB/T10347 and food strain preparations QB/T4574, Q/XSAJY0001S, Q/XSASW0015S |
||||||||||||||||||||||
|
纳入标准: |
1性别不限,年龄在 18-70 岁之间; 2口腔卫生良好,无牙齿结构异常 3结合病史及临床检查,临床上尚未确诊为“龋病”的健康人群(可以患有其他口腔疾病); 4良好的依从性,愿意保持随访; 5愿意参加本次研究,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Gender is not limited, age between 18 and 70 years old; 2. Good oral hygiene, no abnormal dental structure 3. Healthy people who have not been clinically diagnosed as "caries" (can suffer from other oral diseases) according to their medical history and clinical examination; 4. Good compliance, willing to keep follow-up; 5. Be willing to participate in this study and sign the informed consent. |
||||||||||||||||||||||
|
排除标准: |
1志愿者同时间参与其他医学研究项目; 2对植物益生菌成分过敏者; 3患有精神疾病或认知功能障碍者; 4不能遵医嘱使用益生菌口含片和按时复诊者; 5孕妇及哺乳期妇女; 6三个月内使用过免疫调节剂、激素类药物者; 7近期?重??术?尚未恢复者; 8已知原发性免疫缺陷病史; 9已知患有活动性肺结核; 10已知异体器官移植史和异体造??细胞移植史; 11已知存在 HIV 感染者及携带者(HIV 抗体阳性); 12已知存在乙肝感染及携带者(大三阳与小三阳) 13处于活动期或临床控制不佳的严重感染; 14症状性充血性心力衰竭(纽约?脏病协会分级Ⅱ级)或症状性或控制不佳的?律失常; 15研究人员认为其他原因不适合此研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Volunteers participate in other medical research projects at the same time; 2 Allergic to plant probiotics; 3. People with mental illness or cognitive impairment; 4 Patients who could not follow the doctor's advice to use probiotic oral lozenges and return to the doctor on time; 5 Pregnant and lactating women; 6. Those who have used immunomodulators and hormone drugs within three months; 7 Patients who have not recovered from major surgery recently; 8 Known history of primary immunodeficiency; 9 known to have active tuberculosis; 10 Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation; 11 Known HIV infected persons and carriers (HIV antibody positive); 12 Known hepatitis B infection and carriers (Dasanyang and Xiaosanyang) 13 Serious infections that are active or poorly controlled clinically; Symptomatic congestive heart failure (New York Heart Association Grade II) or symptomatic or poorly controlled arrhythmias; 15 The researchers considered that other reasons were not suitable for this researcher. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-09-01 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
简单随机 由研究人员采用随机数字表法产生随机数列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Researchers use random number table to get random sequence. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
none |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
none |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |